Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXPECT: esketamine and treatment expectation in acute major depressive disorder
2020-000784-23Phase 3Completed
- Sponsor
- Philipps-Universität Marburg
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of esketamine in major depressive disorder (MDD) (4 arms), sponsored by Philipps-Universität Marburg. Primary endpoint: Brain activation in reward, emotion, placebo, antidepressant response, and MDD pathophysiology networks. Started Jul 2020; status: completed.
02
Drugs
esketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2020-000784-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000784-23.